<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137255/" ref="ordinalpos=1959&amp;ncbi_uid=6137743&amp;link_uid=PMC3137255" image-link="/pmc/articles/PMC3137255/figure/cjc-30-01-013-g002/" class="imagepopup">Figure 2.A simplified model for Hh <span class="highlight" style="background-color:">signaling</span> in mammalian cells. SMO is the key signal transducer of the Hh <span class="highlight" style="background-color:">pathway</span>. A, in the absence of the Hh ligands, the Hh receptor PTC is thought to be localized in the cilium to inhibit SMO <span class="highlight" style="background-color:">signaling</span> (via an unknown mechanism). Gli molecules are processed with the help of Su(Fu)/KIF7 molecules into repressor forms, which disable the Hh <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. B, in the presence of Hh, PTC is thought to be shuttled out of cilium and is unable to inhibit SMO. Co-receptors of Hh ligands include CDO, BOC, and GAS1. Hh reception promotes SMO conformational change, facilitating Gli activation (GMA), stimulating Hh target gene expression. This process can be inhibited by KIF7 and Su (Fu). (Positive regulators are in red, negative regulators are in blue and target genes are in orange.).  From: Clinical implications of hedgehog <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> inhibitors. </a></div><br /><div class="p4l_captionBody"></div></div>